Healthcare products company West Pharmaceutical Services (NYSE: WST) will be reporting earnings this Thursday morning. Here’s what to expect.

West Pharmaceutical Services beat analysts’ revenue expectations last quarter, reporting revenues of $805 million, up 7.5% year on year. It was a strong quarter for the company, with a solid beat of analysts’ full-year EPS guidance estimates and a beat of analysts’ EPS estimates.

Is West Pharmaceutical Services a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting West Pharmaceutical Services’s revenue to grow 11.6% year on year, improving from its flat revenue in the same quarter last year.

The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. West Pharmaceutical Services rarely misses Wall Street’s revenue estimates.

With West Pharmaceutical Services being the first among its peers to report earnings this season, we don’t have anywhere else to look to get a hint at how this quarter will unravel for life sciences tools & services stocks. However, there has been positive investor sentiment in the segment, with share prices up 7.5% on average over the last month. West Pharmaceutical Services is up 14.1% during the same time .

WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.

This is what the early days of Palantir looked like before it became a $437 billion giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.